The Rise of Biosimilars and Biobetters
The global protein engineering market is a dynamic and rapidly expanding sector within the biotechnology and pharmaceutical industries. Protein engineering involves the design and creation of novel proteins or the modification of existing ones to enhance their function, stability, and specificity for various applications. This field is revolutionizing drug discovery, biomanufacturing, and diagnostics by enabling the development of highly effective and targeted therapeutic proteins. The market’s robust growth is fundamentally driven by the escalating demand for protein-based therapeutics and the increasing investment in advanced biotechnological research.
Market insights reveal a strong financial and technological trajectory. The global protein engineering market was valued at approximately USD 3.1 billion in 2023 and is projected to reach an impressive USD 13.13 billion by 2032, reflecting a substantial Compound Annual Growth Rate (CAGR) of about 17.4%. This remarkable growth rate underscores the critical role of engineered proteins in addressing a wide range of chronic diseases and the continuous innovation in the field, from rational design to the emerging use of artificial intelligence.
FAQs
What is a biosimilar? A biosimilar is a biological drug that is highly similar to an already approved biologic drug, with no clinically meaningful differences in terms of safety, purity, and potency.
How does protein engineering contribute to "biobetters"? Biobetters are enhanced versions of existing biologics. Protein engineering is used to improve their therapeutic properties, such as a longer half-life or reduced immunogenicity, offering a significant advantage over the original drug.